You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NHLBISummary Lung diseases, such as interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and acute viral infection are major leading causes of death worldwide. The recent increase due to air pollution, tobacco smoking is and use of E-cigarettes has grown rapidly in the US contributing to a sharp increase in chronic lung diseases. IPF is ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters
SBC: NYTRICX INC Topic: NHLBIAbstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
SBC: MOONLIGHT THERAPEUTICS, INC. Topic: NIAIDThe following contains proprietary/privileged information that Moonlight Therapeutics requests not be released to persons outside the government, except for purposes of review and evaluation Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within theSkin) patch for the Treatment of Peanut Allergy Food allergies affect 30 million people in the USA and 17 million in ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
High-throughput functional analysis and clinical relevance of all possible variants of a gene
SBC: HELIGENICS, INC. Topic: NHGRIModern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Low-Cost Wearable Connected Health Device for Monitoring Environmental Pollution Triggers of Asthma in Communities with Health Disparities
SBC: WI-SENSE LLC Topic: NHLBIProject Abstract Asthma affects 25 million Americans, and chronic obstructive pulmonary disease (COPD) affects 16 million,together costing 130 billion USD annually to the US healthcare system. Asthma is more prevalent in AfricanAmerican population (10.6%) than white population (7.7%). Poverty level has an impact as well, with twice asmuch asthma incidence in people below 100% of the poverty thresh ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities
SBC: EPIVAX, INC. Topic: NIAIDABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Enhanced renal dialysis membrane performance using lipocalin modified substrates
SBC: HIBAR Microsciences, LLC Topic: 400PROJECT SUMMARY: It is estimated that more than 30 million American adults have chronic kidney disease (CKD), with nearly 800,000 living with end-stage renal disease (ESRD). People with chronic diseases such as diabetes, high blood pressure, and heart disease are at a higher risk for CKD. Because their kidneys no longer function, individuals with ESRD often rely on hemodialysis to remove waste fro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Point-of-care lateral flow immunoassay for diagnosis of pertussis
SBC: DXDISCOVERY INC Topic: NIAIDPertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Recognition of O-GlcNAc Modified Proteins Using Site-Specific Antibodies
SBC: GLYCOSCIENTIFIC, L.L.C. Topic: NHLBIPulmonary arterial hypertension (PAH) is a progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. PAH is a disease of pulmonary vascular endothelial dysfunction with nitric oxide (NO) deficiency and dysregulated glucose metabolism/utilization. It is a heterogeneous disorder likely to be comprised of overlappi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: 100Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health